Question special
Chief Resident

Though not powered for improved renal outcome, the DAPA HF trial showed that renal profile for SGLT2i is quite favorable. This was later proved for SGLT2i in Credence trial that was powered for renal outcomes.

Do we foresee more use of this medication in renal (both diabetic and non diabetic) pts to slow renal disease progression irrespective of presence of HF. Especially in pts on max dose ACE/ARB or intolerant/allerigc to them. Is it too early to say?